Molecular characterization of ovarian squamous cell carcinoma originating from mature teratoma

被引:0
作者
Chao, Angel [1 ,2 ]
Lai, Chyong-Huey [1 ,2 ]
Chao, An-Shine [1 ,3 ]
Lin, Chiao-Yun [2 ]
Wang, You-Chen [2 ,4 ]
Huang, Huei-Jean [1 ,2 ]
Wu, Ren-Chin [5 ,6 ]
机构
[1] Chang Gung Univ Coll Med, Linkou Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taoyuan, Taiwan
[2] Chang Gung Mem Hosp Linkou, Gynecol Canc Res Ctr, Taoyuan, Taiwan
[3] New Taipei City Municipal Tu Cheng Hosp, Dept Obstet & Gynecol, New Taipei City, Taiwan
[4] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Keelung, Taiwan
[5] Chang Gung Mem Hosp Linkou, Dept Anat Pathol, Taoyuan, Taiwan
[6] Chang Gung Univ Coll Med, Taoyuan, Taiwan
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2025年 / 103卷 / 01期
关键词
Squamous cell carcinoma; Ovary; Mature teratoma; Molecular inversion probe array; Targeted sequencing; Meiosis; Endoduplication; CYSTIC TERATOMA; GENETICS; MULTICENTER; BIOLOGY; CANCER;
D O I
10.1007/s00109-024-02505-w
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Squamous cell carcinoma (SCC) of the ovary, an uncommon form of gynecologic cancer, typically originates from the malignant transformation of a pre-existing mature ovarian teratoma (MOT). However, due to its rarity, the molecular pathways driving its development are not well understood. To address this knowledge gap, we performed molecular inversion probe (MIP) array analysis and targeted sequencing of 275 cancer susceptibility genes on 11 ovarian SCC samples derived from MOTs. Additionally, we conducted the same molecular tests on two samples of ovarian metastases of SCCs that originated from primary sites outside the ovary, specifically, one from endometrial cancer and one from cervical SCC. Utilizing MIP arrays, we identified failures in meiosis I and II, as well as instances of endoreduplication within haploid ova, in five, two, and four samples of ovarian SCCs arising from MOTs, respectively. Notably, such alterations were absent in samples of ovarian metastases, implying that primary ovarian SCCs may derive from teratoma cells. Targeted sequencing identified TP53 as the most frequently mutated gene in ovarian SCCs, occurring in 82% of cases. This was followed by mutations in PIK3CA (36%), PTEN (27%), and KMT2D (27%). Furthermore, mutations in CDKN2A and copy number loss of 9p21.3 were observed in 54.5% of the cohort. In summary, our study elucidates the germ cell origin of ovarian SCC and provides a comprehensive analysis of its genomic landscape, which may assist in differential diagnosis and inform the development of targeted therapies with potential clinical benefits.
引用
收藏
页码:101 / 111
页数:11
相关论文
共 24 条
[11]   Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial [J].
Konstantinopoulos, Panagiotis A. ;
Barry, William T. ;
Birrer, Michael ;
Westin, Shannon N. ;
Cadoo, Karen A. ;
Shapiro, Geoffrey, I ;
Mayer, Erica L. ;
O'Cearbhaill, Roisin E. ;
Coleman, Robert L. ;
Kochupurakkal, Bose ;
Whalen, Christin ;
Curtis, Jennifer ;
Farooq, Sarah ;
Luo, Weixiu ;
Eismann, Julia ;
Buss, Mary K. ;
Aghajanian, Carol ;
Mills, Gordon B. ;
Palakurthi, Sangeetha ;
Kirschmeier, Paul ;
Liu, Joyce ;
Cantley, Lewis C. ;
Kaufmann, Scott H. ;
Swisher, Elizabeth M. ;
D'Andrea, Alan D. ;
Winer, Eric ;
Wulf, Gerburg M. ;
Matulonis, Ursula A. .
LANCET ONCOLOGY, 2019, 20 (04) :570-580
[12]   Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review [J].
Li, Congcong ;
Zhang, Qing ;
Zhang, Siying ;
Dong, Ruifen ;
Sun, Chenggong ;
Qiu, Chunping ;
Zhang, Zhiwei ;
Yang, Xingsheng ;
Kong, Beihua .
BMC CANCER, 2019, 19 (1)
[13]   PARTHENOGENIC ORIGIN OF BENIGN OVARIAN TERATOMAS [J].
LINDER, D ;
MCCAW, BK ;
HECHT, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (02) :63-66
[15]   FURTHER EVIDENCE FOR POST-MEIOTIC ORIGIN OF TERATOMAS IN HUMAN FEMALE [J].
LINDER, D ;
POWER, J .
ANNALS OF HUMAN GENETICS, 1970, 34 :21-&
[16]   Preoperative diagnosis of malignant transformation arising from mature cystic teratoma of the ovary [J].
Mori, Y ;
Nishii, H ;
Takabe, K ;
Shinozaki, H ;
Matsumoto, N ;
Suzuki, K ;
Tanabe, H ;
Watanabe, A ;
Ochiai, K ;
Tanaka, T .
GYNECOLOGIC ONCOLOGY, 2003, 90 (02) :338-341
[17]   The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something? [J].
Ottaviano, Margaret ;
Giunta, Emilio Francesco ;
Rescigno, Pasquale ;
Pereira Mestre, Ricardo ;
Marandino, Laura ;
Tortora, Marianna ;
Riccio, Vittorio ;
Parola, Sara ;
Casula, Milena ;
Paliogiannis, Panagiotis ;
Cossu, Antonio ;
Vogl, Ursula Maria ;
Bosso, Davide ;
Rosanova, Mario ;
Mazzola, Brunello ;
Daniele, Bruno ;
Palmieri, Giuseppe ;
Palmieri, Giovannella .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
[18]   THE ORIGIN OF OVARIAN TERATOMAS [J].
PARRINGTON, JM ;
WEST, LF ;
POVEY, S .
JOURNAL OF MEDICAL GENETICS, 1984, 21 (01) :4-12
[19]  
Patil S R, 1978, Birth Defects Orig Artic Ser, V14, P297
[20]   Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study [J].
Rugo, Hope S. ;
Lerebours, Florence ;
Ciruelos, Eva ;
Drullinsky, Pamela ;
Ruiz-Borrego, Manuel ;
Neven, Patrick ;
Park, Yeon Hee ;
Prat, Aleix ;
Bachelot, Thomas ;
Juric, Dejan ;
Turner, Nicholas ;
Sophos, Nickolas ;
Zarate, Juan Pablo ;
Arce, Christina ;
Shen, Yu-Ming ;
Turner, Stuart ;
Kanakamedala, Hemanth ;
Hsu, Wei-Chun ;
Chia, Stephen .
LANCET ONCOLOGY, 2021, 22 (04) :489-498